Shanghai, April 22, 2024 – Recently, the wireless ECG recorder launched by Omron Healthcare (hereinafter referred to as "Omron") has made a shocking appearance at major industry exhibitions and officially pre-sold to the public today. Thanks to its portable, compact design and high precision, the new wireless ECG recorder can meet the health needs of patients for ECG monitoring anytime and anywhere, and supports online and offline dual-mode monitoring, providing patients with intelligent analysis and early warning of atrial fibrillation risk. As Omron's innovation in the field of cardiovascular and cerebrovascular diseases for 50 years, this product will not only effectively promote the early diagnosis and treatment of cardiovascular and cerebrovascular diseases in China, but also open up a new era of multi-scene ECG monitoring. This new product launch also reflects Omron's solid commitment to cardiovascular and cerebrovascular health protection and the in-depth layout of the transformation from daily blood pressure monitoring to complication risk prevention.
The wireless ECG recorder is newly launched to help patients achieve "abnormal heart, that is, action"
As the main risk factor for cardiovascular diseases, the prevalence of hypertension is continuing to rise, and the resulting atrial fibrillation, stroke and other diseases have become the focus of cardiovascular and cerebrovascular prevention and treatment. Atrial fibrillation significantly increases the risk of major cardiovascular and cerebrovascular diseases. The risk of stroke in patients with atrial fibrillation is 4~5 times that of patients without atrial fibrillation. Atrial fibrillation can triple the prevalence of heart failure and worsen the symptoms of heart failure. *Therefore, the early prevention and effective management of hypertension through electrocardiogram monitoring and other means is becoming increasingly important. In this context, the "Healthy China Action - Implementation Plan for the Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (2023-2030)" clearly proposes to "strengthen the threshold and move forward, and innovate the path of prevention and treatment of cardiovascular and cerebrovascular diseases". In this regard, Omron continues to take innovation as the driving force and help solve the problem of cardiovascular and cerebrovascular prevention and treatment in China by launching advanced products such as wireless ECG recorders.
Convenient design: ECG monitoring anytime, anywhere in multiple scenarios
The wireless ECG recorder breaks the technical barrier that ECG monitoring can only be carried out in hospitals, and provides daily cardiovascular and cerebrovascular health management for patients with heart diseases such as hypertension and atrial fibrillation. Its compact design, easy to grip and carry can help patients with arrhythmia to monitor ECG anytime and anywhere in multiple scenarios such as home, office, and outing. This can not only alleviate the inner anxiety of patients, but also effectively prevent the occurrence of missed diagnosis of cardiovascular and cerebrovascular diseases, and provide strong support for patients to realize "heart movement, that is, action".
With its convenient, accurate and intelligent advantages, wireless ECG recorder opens up a new era of multi-scene ECG monitoring
Humanized care: support online and offline dual monitoring mode
What's more innovative and humane is that the wireless ECG recorder is equipped with two ECG measurement modes: online and offline. When a patient feels unwell, the wireless ECG recorder can automatically save the ECG at that time after only 30 seconds of measurement, so that the patient can understand in real time, trace his heart condition and seek medical attention in time. The monitoring results also provide an important reference for subsequent doctors' diagnosis and maximize the protection of patients' health.
Intelligent algorithm analysis: directly connected to the OMRON Plus APP to warn of the risk of atrial fibrillation
The device can also be directly connected to the OMRON Plus APP, relying on its atrial fibrillation risk identification algorithm, to warn patients of atrial fibrillation risk, and provide intelligent and personalized cardiovascular and cerebrovascular disease analysis and management suggestions. In addition, OMRON Plus ECG (ECG Analysis Prompt Software) has been approved for the "Medical Device Registration Certificate of the People's Republic of China", which not only reflects its professionalism and accuracy, but also demonstrates Omron's continuous innovation in the field of intelligent chronic disease management.
The OMRON Plus app relies on its atrial fibrillation risk identification algorithm to warn patients of atrial fibrillation risk
Mr. Zhao Yao, Director & General Manager of Omron Healthcare (China) Co., Ltd., said: "As an expert in the field of chronic disease management, Omron adheres to the vision of 'Going for ZERO preventive medicine, making the world healthier', always focusing on consumer needs, and is committed to integrating innovative technology into daily chronic disease management. Starting from the launch of the wireless ECG recorder, Omron will continue to rely on the technological innovation of half a century of excellence to bring more convenient and intelligent health management equipment to consumers, further deepen the layout in the field of cardiovascular and cerebrovascular diseases, and at the same time improve patients' awareness and management level of their own health with practical actions such as popular science and patient education, and help the steady realization of strategies such as 'Healthy China 2030'. ”
*Cardiac Electrophysiology and Pacing Branch of Chinese Medical Association, Cardiac Rhythm Professional Committee of Chinese Medical Doctor Association, Atrial Fibrillation Prevention and Treatment Expert Working Committee of China Atrial Fibrillation Center Alliance. Atrial fibrillation: current understanding and treatment recommendations (2021) [J]. Chinese Journal of Arrhythmias, 2022, 26(1):15-88.